VIA
VERV

Virtus Investment Advisers’s Verve Therapeutics VERV Stock Holding History

Virtus Investment Advisers’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,879
Closed -$167K – 476
2025
Q2 		$167K Sell
14,879
-11,469
-44% -$65.4K 0.06% 295
2025
Q1 		$120K Buy
+26,348
New +$176K 0.03% 392

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Virtus Investment Advisers's VERV Position: Q3 2025 in Review

Virtus Investment Advisers sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 14,879 shares — an estimated $167K sold.

Virtus Investment Advisers first reported a position in VERV in Q1 2025 and held it in 2 quarters. The position peaked at $167K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Virtus Investment Advisers reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Virtus Investment Advisers sold 14,879 Verve Therapeutics shares in Q3 2025, an estimated $167K.
  • Virtus Investment Advisers first reported a position in Verve Therapeutics in Q1 2025 and held it in 2 quarters.
  • Virtus Investment Advisers's Verve Therapeutics position peaked at $167K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Virtus Investment Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.